Validation Program Commences-FDA 510(k) - First Participant
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The study is being conducted by IQVIA-MCRA to ensure adherence to protocols and regulatory standards. This program follows a successful pilot study that demonstrated high sensitivity and specificity, exceeding target thresholds.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Blinklab
- Morocco's Nationwide Government-Funded Autism Screening
- Trading Halt
- Clinical Trial Network for Pivotal FDA Study Complete
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Blinklab
- BlinkLab Launches Pivotal US FDA Trial for AI Smartphone Autism Diagnostic
- BlinkLab Secures A$17.5M to Launch Autism Diagnostic Aid
- 2026 Annual Report & Appendix 4E
- European ADHD Study Delivers Positive Results
Follow Blinklab into a list and get an email when it puts out news.
Follow Blinklab